Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19?
Med Hypotheses
; 144: 110224, 2020 Nov.
Article
in English
| MEDLINE | ID: covidwho-733694
ABSTRACT
INTRODUCTION:
SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute respiratory distress syndrome (ARDS). Patients with mild symptoms also show significant changes on pulmonary CT-scan suggestive of severe inflammatory involvement.HYPOTHESIS:
The overall hypothesis is that HBO2 is safe and reduces the inflammatory response in COVID-19 pneumonitis by attenuation of the innate immune system, increase hypoxia tolerance and thereby prevent organ failure and reduce mortality. EVALUATION OF THEHYPOTHESIS:
HBO2 is used in clinical practice to treat inflammatory conditions but has not been scientifically evaluated for COVID-19. Experimental and empirical data suggests that HBO2 may reduce inflammatory response in COVID-19. However, there are concerns regarding pulmonary safety in patients with pre-existing viral pneumonitis. EMPIRICAL DATA Anecdotes from "compassionate use" and two published case reports show promising results. CONSEQUENCES OF THE HYPOTHESIS ANDDISCUSSION:
Small prospective clinical trials are on the way and we are conducting a randomized clinical trial.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Oxygen
/
COVID-19
/
Hyperbaric Oxygenation
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Animals
/
Humans
Language:
English
Journal:
Med Hypotheses
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS